NAT10 and esophageal squamous cell carcinoma: Based on this candidate, optimization of the drug structure is expected to generate more potent and selective compounds for drug discovery.[28] Collectively, we provide a new strategy for combating the metastasis of ESCC by inhibiting NAT10‐catalyzed ac4C modification and repairing the subsequent autophagy‐lysosomal dysfunction, shedding light on the treatment of this lethal disease.